Resistance to immunotherapies: Mechanisms to overcome acquired resistance
Related
Watch on demand our third session of 'New Directions in Immuno-oncology: Response and Resistance' held on February 18, 2021
Webinar objectives
- Discuss new directions for selective pathogenic roles for IDO1 in metastatic vasculogenesis and retinopathy
- Identify novel tools for integrated screens with single-cell readouts
- Review predictive biomarkers for immunotherapy response and resistance
Abcam is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program. Interested in receiving P.A.C.E credit for this educational session? Request credit here!
Speakers
- George Prendergast, The Lankenau Institute for Medical Research, USA
- IDO/TDO targeting for cancer therapy: the path forward
- Timestamp: 7:20 - 34:12
- Mari Mino-Kenudson, Massachusetts General Hospital, USA
- Primary and acquired resistance to immunotherapies in lung cancer: Mechanisms and predictive biomarkers
- Timestamp: 35:25 - 59:15
- Benjamin Izar, Columbia University, USA
- Pooled screens with multi-modal single-cell profiling to define mechanisms of cancer immune evasion
- Timestamp: 1:00:27 - 1:28:17
- Rüdiger Greinert, Elbekliniken Stade/Buxtehude, Germany
- Use of a miRNA (FirePlex) assay for biomarker identification in clinical settings
- Timestamp: 1:29:16 - 1:58:05
Contact
Have a question? Please contact the Abcam Events Team.